WOLFGANG WINKELMAYER to Epoetin Alfa
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Epoetin Alfa.
Connection Strength
0.538
-
Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol. 2016 Oct; 27(10):3129-3138.
Score: 0.134
-
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
Score: 0.126
-
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.
Score: 0.124
-
Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014 May; 174(5):699-707.
Score: 0.118
-
Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009 Oct; 18(10):932-40.
Score: 0.021
-
Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004 Oct; 66(4):1712; author reply 1712-3.
Score: 0.015